Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-76920 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- FABP5 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 1 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references FABP5 enhances malignancies of lower-grade gliomas via canonical activation of NF-κB signaling.
Wang Y, Wahafu A, Wu W, Xiang J, Huo L, Ma X, Wang N, Liu H, Bai X, Xu D, Xie W, Wang M, Wang J
Journal of cellular and molecular medicine 2021 May;25(9):4487-4500
Journal of cellular and molecular medicine 2021 May;25(9):4487-4500
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of FABP5 in extracts of various cell lines. Samples were incubated with FABP5 polyclonal antibody (Product # PA5-76920).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of FABP5 in paraffin-embedded rat kidney. Samples were incubated with FABP5 polyclonal antibody (Product # PA5-76920).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- FIGURE 2 FABP5 expression was elevated in malignant LGGs. A, Expression of FABP5 in gliomas according to WHO classification by using CGGA database (** P < .01, with one-way ANOVA followed by Dunnett's post-test). B, Expression of FABP5 in LGGs based on IDH and 1p/19q status by using CGGA database (** P < .01, with one-way ANOVA followed by Dunnett's post-test). C-D, Expression of FABP5 in primary or recurrent gliomas C, and LGGs D, by using CGGA database (** P < .01, with one-way ANOVA followed by Dunnett's post-test). E, Representative IHC images of FABP5 expression in glioma samples and non-tumour tissues (Upper panel: H&E staining, Middle panel: FABP5 expression, Lower panel: MRI scanning). F-H, Proportion distribution for FABP5 expression in glioma samples. Samples were clustered by IDH and 1p/19q status (F: patient samples, G: CGGA database) and WHO grade (H: CGGA database)